RELATED CONTENT
NEWS
- Crystal ball time: Looking ahead at T-DM1, Invokana, BG-12
- One year Herceptin treatment limit gives Roche headroom for Perjeta and T-DM1
- T-DM1 show overall survival advantage as Roche/Genentech make US and EU filings
- Perjeta US OK tops winning week for Genentech/Roche in breast cancer
FEATURES
- A big job for a little biotech: SK Bio's growth plans
- The Valeant way: Michael Pearson's two-year top 15 route march

